Mineralocorticoid Receptor Blockade in Chronic Kidney Disease | Zendy

Andrew S. Bomback | Zendy; Philip J. Klemmer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Mineralocorticoid Receptor Blockade in Chronic Kidney Disease

Author(s) -

Andrew S. Bomback,

Philip J. Klemmer

Publication year - 2012

Publication title -

blood purification

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.686

H-Index - 57

eISSN - 1421-9735

pISSN - 0253-5068

DOI - 10.1159/000334161

Subject(s) - mineralocorticoid receptor , hyperkalemia , medicine , kidney disease , heart failure , aldosterone , mineralocorticoid , blockade , eplerenone , angiotensin converting enzyme , cardiology , disease , endocrinology , intensive care medicine , receptor , blood pressure

Mineralocorticoid receptor blockers (MRBs) have proven highly successful in the treatment of congestive heart failure and resistant hypertension. In contrast, their use in chronic kidney disease (CKD) has lagged due to the concern of hyperkalemia and, possibly, because of the incorrect assumption that traditional therapy with angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers consistently reduce aldosterone activity in all patients. Low-dose MRB therapy may offer additional antihypertensive and unique anti-inflammatory benefits in select CKD populations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research